Why Allarity Therapeutics Stock Is Tanking Today

Allarity Therapeutics Inc ALLR shares are diving Thursday after the company announced the pricing of a public offering.

What Happened: Allarity shares surged on Wednesday after the company said initial data from the Phase 2 trial of Ixempra showed potential for improved clinical benefit in DRP-selected metastatic breast cancer patients.

The stock traded up to around the $13 level before pulling back. Allarity shares closed the day up 31.4% at $8.28. 

Following Wednesday's move, the company priced a public offering of 2.44 million shares and common warrants to purchase up to 2.44 million shares at a combined price of $4.50 per share. Allarity anticipates aggregate gross proceeds of approximatley $11 million from the offering. 

Allarity intends to use a portion of the proceeds to pay account payables and accrued liabilities outstanding, to make payments under certain license agreements, to pay off a certain outstanding promissory note, to conduct clinical trials and for working capital. The offering is expected to close on or about July 10. 

Allarity is a clinical-stage pharmaceutical company developing novel oncology therapeutics with drug-specific DRP companion diagnostics for personalized cancer care.

See Also: Skye Completes Production Of Cannabinoid Based Drug In Preparation For Glaucoma Clinical Trial

ALLR Price Action: Allarity shares were down 52% at $3.96 at the time of publication, according to Benzinga Pro.

Photo: Lorenzo Cafaro from Pixabay.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsOfferingsMoverswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!